WaferGen Biosystems
WaferGen Biosystems is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at WaferGen Biosystems.
WaferGen Biosystems is a company.
Key people at WaferGen Biosystems.
Key people at WaferGen Biosystems.
WaferGen Bio-systems, Inc. was a biotechnology company specializing in innovative genomic technology solutions for single-cell analysis and clinical research.[1][2][3] It developed and manufactured systems like the ICELL8® Single-Cell System, which isolates thousands of single cells for selection and processing in analyses such as next-generation sequencing (NGS), and the Apollo™ 324 system for preparing NGS-ready libraries from clinical DNA and RNA samples.[2] These tools targeted life sciences, pharmaceutical, and clinical labs, addressing challenges in molecular and single-cell level biological analysis by enabling precise cell isolation and efficient library prep.[1][2][3] The company served researchers in the US, Canada, Europe, and beyond, with reported revenue of $7 million, $55.6 million in funding, and about 22 employees before its acquisition.[2]
Founded in 2003 and headquartered in Fremont, California, WaferGen focused on biotech tools including qPCR, mRNA/ncRNA profiling, SNP genotyping, and real-time PCR, evolving into a leader in single-cell genomics.[2] It traded on NASDAQ under ticker WGBS and built early traction through automation systems for genomics research.[2] Key pivotal moments included developing the ICELL8 and Apollo platforms, which positioned it for growth in clinical and pharma applications.[2] The company's journey culminated in its acquisition by Takara Bio USA Holdings, Inc. (now part of Takara Bio USA), integrating its technologies into a larger biotech portfolio.[2][4][5]
WaferGen stood out in the biotech tools space through:
WaferGen rode the single-cell genomics boom, a key trend in precision medicine and drug discovery where analyzing individual cells uncovers heterogeneity missed by bulk methods.[1][2] Timing aligned with NGS advancements and rising demand for clinical research tools post-2010s, fueled by pharma's push for personalized therapies and cancer profiling.[3] Market forces like expanding biotech R&D (e.g., in immunotherapy) favored its automation, reducing manual labor and errors in high-stakes labs.[2] It influenced the ecosystem by pioneering accessible single-cell tech, now amplified through Takara Bio's global reach, contributing to scalable solutions in a market projected for rapid growth.[4][5]
Post-acquisition by Takara Bio USA, WaferGen's technologies persist under a stronger platform, likely expanding ICELL8 and Apollo integrations with Takara's NGS and bio tools.[2][4][5] Trends like AI-driven genomics and multi-omics will shape its legacy, enhancing single-cell applications in CAR-T therapies and spatial biology. Its influence evolves from standalone innovator to embedded asset in Takara's portfolio, potentially accelerating adoption in global clinical pipelines—reinforcing how targeted biotech tools like WaferGen's fuel the precision era.[2][5]